All In Biotech

NDA 211728 · Urogen Pharma

Jelmyto

Mitomycin · Pyelocalyceal

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Oct 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Apr 15, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

286

89 Phase 3, 41 recruiting

FAERS reports

3,208

2,668 serious, 398 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 9, 2025.

JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). ( 1 )

Mechanism: Mitomycin inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 2020 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
  • JELMYTO · MITOMYCIN 40MG/VIAL · POWDER, PYELOCALYCEAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mitomycin" as an intervention, any sponsor and status, largest first.

All 286 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use384
  • nausea165
  • diarrhoea158
  • fatigue118
  • thrombocytopenia112
  • vomiting111
  • neutropenia109
  • drug ineffective108
  • rash107
  • pancytopenia104
  • disease progression100
  • pyrexia95

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200467
200577
200686
200796
2008125
200979
201094
2011137
2012134
2013129
201486
2015112
201697
201786
2018127
2019160
2020157
2021186
2022212
2023148
2024252
2025342
2026219

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Jelmyto (Mitomycin) · HCPCS J9281

2024 spending

$35.3M

Beneficiaries

377

1,607 claims

Per beneficiary

$93,546

2024 ASP limit $303.83 per unit

View as table
YearSpending
2020$0
2021$26,431,754
2022$29,464,809
2023$38,116,311
2024$35,266,741

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,194 on PubMed

Sponsor: Urogen Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.